NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, announces that the ongoing international multicenter phase III study on the company ́s drug candidate CicloMulsion® (the C ...

NeuroVive Pharmaceutical AB (publ) has initiated a collaboration within investor relations communication with Laika Consulting, a company that specializes in helping companies and other entities with ...

Lund (Sweden) - March 22, 2013, NeuroVive, a leading mitochondrial medicine company, announces that the 600th patient has been recruited to a pivotal Phase III European, multi-center trial (CIRCUS tri ...

Lund (Sweden) - December 3, 2012. NeuroVive announces publication of the results of a Phase I clinical trial of lead product CicloMulsion® in the scientific journal Clinical Drug Investigation. The pa ...

Beijing (China) and Lund (Sweden) - November 20, 2012. NeuroVive, the leading mitochondrial medicine company, today announces a collaboration agreement with Sihuan Pharmaceutical Holdings Group Ltd. f ...

Note: This is an English version of a press release communicated by NeuroVive 2012-10-08 Ongar (UK) and Lund (Sweden) - 8 October, 2012. UK-based Mitopharm Limited, a subsidiary of Selcia Holdings Lim ...

Lund, Sweden, 15 December 2011

Lund, Sweden / Leiden, the Netherlands, 29 September 2011 NeuroVive Pharmaceutical AB (publ) and to-BBB, the Dutch brain drug delivery company, have been awarded a grant of €1 million through the Eure ...

Ongar (UK) and Lund (Sweden), September 19, 2011 - UK-based contract research organisation Selcia Limited and Swedish drug development company NeuroVive Pharmaceutical AB (publ) have signed a signific ...

Lund, Sweden - September 15, 2011 - A U.S. magazine called Pharmaceutical Formulation & Quality (circulation to 20,000 senior pharmaceutical executives throughout the US and Canada) has just published ...

Investigator-initiated European multicenter trial of 1,000 acute heart attack patients will examine the ability of cyclosporine to protect cardiac tissue

Note: This is an English version of a press release communicated by NeuroVive 2011-03-02 Phase II/III study will determine the safety and efficacy of NeuroSTAT® in patients with moderate to severe tra ...